SCHEMBL3655211

SCHEMBL3655211

CC(C)(C)c1cc(C(=O)Nc2ccc(O)cc2)cc(C(C)(C)C)c1O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NQO2 P16083 2/20 0.62
SNCA P37840 3/20 0.59
TOP1 P11387 1/20 0.54
TOP2A P11388 1/20 0.54
TOP2B Q02880 1/20 0.54
NPC1 O15118 4/20 0.53
RAB9A P51151 4/20 0.53
TP53 P04637 2/20 0.53
ALDH1A1 P00352 2/20 0.51
GAA P10253 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
HDAC3 O15379 2/20 0.50
HDAC6 Q9UBN7 2/20 0.50
POLB P06746 1/20 0.50
GFER P55789 1/20 0.50
DEGS1 O15121 2/20 0.49
HDAC11 Q96DB2 1/20 0.47
HDAC8 Q9BY41 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.46
TRPV1 Q8NER1 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4652364 0.90 MEN1 (0.56) NQO2SNCATOP1TOP2ATOP2B
SCHEMBL11807786 0.89 RAB9A (0.59) NQO2SNCATOP1TOP2ATOP2B
SCHEMBL5925570 0.88 MEN1 (0.55) SNCATOP1TOP2ATOP2BNPC1
SCHEMBL4319185 0.88 SNCA (0.65) NQO2SNCATOP1TOP2ATOP2B
SCHEMBL6544007 0.86 GAA (0.50) NQO2SNCATOP1TOP2ATOP2B
SCHEMBL3660580 0.83 MEN1 (0.62) SNCATOP1TOP2ATOP2BNPC1
SCHEMBL9417252 0.83 NR1H4 (0.67) TP53ALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL4322184 0.83 KMT2A (0.57) NPC1RAB9AALDH1A1POLBSMN1; SMN2
SCHEMBL7551932 0.82 TNFRSF1A (0.62) SNCARAB9ATP53ALDH1A1TDP1
SCHEMBL12324390 0.81 GAA (0.53) ALDH1A1GAATDP1POLBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9364424-B2 Topical cosmetic skin lightening compositions and methods of use thereof STIEFEL LABORATORIES, INC. (US) 2016-06-14 US disclosed
US-20160074315-A1 TOPICAL COSMETIC SKIN LIGHTENING COMPOSITIONS AND METHODS OF USE THEREOF STIEFEL LABORATORIES, INC. 2016-03-17 US disclosed
EP-2219600-A1 TOPICAL COSMETIC SKIN LIGHTENING COMPOSITIONS AND METHODS OF USE THEREOF STIEFEL LABORATORIES, INC. (US) 2010-08-25 EP disclosed
WO-2009067095-A1 TOPICAL COSMETIC SKIN LIGHTENING COMPOSITIONS AND METHODS OF USE THEREOF STIEFEL LABORATORIES, INC. (US) 2009-05-28 WO disclosed
EP-1604647-B1 Cosmetic composition containing polyorganosiloxane-containing epsilon-polylysine polymer, and polyhydric alcohol, and production thereof CHISSO CORP (JP) 2008-05-07 EP disclosed
US-20060165636-A1 Hair treatment composition and hair cosmetic for damaged hair MEIJI SEIKA KAISHA, LTD. (JP) 2006-07-27 US disclosed
US-20060018867-A1 Cosmetic composition and production thereof ICHIMARU PHARCOS CO., LTD 2006-01-26 US disclosed
EP-1604647-A1 Cosmetic composition containing polyorganosiloxane-containing epsilon-polylysine polymer, and polyhydric alcohol, and production thereof Ichimaru Pharcos Co., Ltd. (JP) 2005-12-14 EP disclosed
EP-1602354-A1 HAIR TREATMENT COMPOSITION AND HAIR COSMETIC FOR DAMAGED HAIR Meiji Seika Kaisha, Ltd. (JP) 2005-12-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060165636-A1 Hair treatment composition and hair cosmetic for damaged hair CUTA, COL14A1, PRKDC NQO2 4400/4885SNCA 3292/4885TOP1 1052/4885
US-20060018867-A1 Cosmetic composition and production thereof CUTA, PARG, TYR NQO2 2345/4885SNCA 947/4885TOP1 611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.